Pivotal Practice Views with the Oncology Brothers

Targeted Oncology's Pivotal Practice Views with Oncology Brothers focuses on recently-approved, practice-changing treatment options across tumors

Key Takeaways From EMERALD: Elacestrant in Patients With Previously Treated ER+, HER2- Metastatic Breast Cancer

May 18th 2023

Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers to review data from the EMERALD trial and discuss use of the oral SERD, elacestrant, in patients with ER+, HER2- advanced breast cancer.

Read More